跳至主要内容
临床试验/NCT03938298
NCT03938298已完成不适用

Substudy of Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (ESTxENDS): Pulmonary Function Substudy (PulmENDS)

University of Bern3 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2019年4月10日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
130
试验地点
3
主要终点
Changes in Lung Clearance Index (LCI)

研究概览

简要总结

--> This is a substudy of the main ESTxENDS trial (NCT03589989). Pulmonary function outcomes should be considered secondary outcomes of the main smoking cessation outcome formulated in NCT03589989.

Cigarette smoking is the leading cause of preventable death in Switzerland and still more than a quarter of the Swiss population smokes cigarettes. Recently, electronic nicotine delivery systems (ENDS; also called vaporizer, e-cigarette or electronic cigarette) have become popular with smokers who want to stop smoking or reduce their exposure to inhaled chemicals since ENDS use appears to be safer than tobacco smoking. The inhaled ENDS aerosol appears safe in laboratory conditions, its long-term effects on pulmonary function remains unknown. This study will therefore investigate the impact of ENDS on lung function in smokers, who attempt to quit using ENDS compared with smokers, receiving only smoking cessation counseling with nicotine replacement therapy (NRT).

Multiple breath washout (MBW) is an established technique for assessment of peripheral airway function in pediatrics and its use is emerging in adult medicine, as it offers a better sensitivity to assess small airway disease before large airway involvement can be detected using conventional pulmonary function tests (PFT - spirometry, body plethysmography and diffusing capacity test). Preliminary evidence from limited studies suggest MBW parameters (LCI, Scond, Sacin) can be impaired in smokers with normal lung function and improve after smoking abstinence.

Primary objective of this substudy is to assess changes in LCI from baseline to 6 months post target quit date (TQD) in cigarette smokers randomized to the intervention group compared to the control group.

For the main ESTxENDS trial (NCT03589989), cigarette smokers motivated to quit smoking cigarettes will be included. Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive standard of care, i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. Participants in the control group will receive only standard of care. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

盲法说明

Statisticians and laboratory personnel will be blinded to group allocation

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed Consent as documented by signature
  • Persons aged 18 or older
  • Currently smoking 5 or more cigarettes a day for at least 12 months
  • Willing to try to quit smoking within the next 3 months
  • Persons providing a valid phone number, a valid email address and/or a valid postal address.

排除标准

  • Known hypersensitivity or allergy to contents of the e-liquid
  • Participation in another study with investigational drug within the 30 days preceding the baseline visit and during the present study where interactions are to be expected
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the scheduled study intervention, i.e. within the first 6-months of the study
  • Persons having used ENDS or tobacco heating systems regularly in the 3 months preceding the baseline visit
  • Persons having used nicotine replacement therapy (NRT) or other medications with demonstrated efficacy as an aid for smoking cessation such as varenicline or bupropion within the 3 months preceding the baseline visit
  • Persons who cannot attend the 6-month follow-up visit for any reason
  • Cannot understand instructions delivered in person or by phone, or otherwise unable to participate in study procedures

结局指标

主要结局

Changes in Lung Clearance Index (LCI)

时间窗: Change from baseline to 6 months post quit date

Measured by multiple breath washout (MBW) of a tracer gas (N2). LCI is defined as the cumulative expired volume/functional residual capacity (CEV/FRC) at 5% and 2.5% tracer gas concentration in the exhaled breath. An LCI with a z-score \< + 1.645 (upper limit of normal according to Singer F et al, PLoS One. 2012;7(4):e36083) is considered normal.

次要结局

  • Changes in Fraction of exhaled nitric oxide (FeNO)(Change from baseline to 6 months post quit date)
  • Forced Expiratory Volume in 1 Second (FEV1)(6 months post quit date)
  • Changes in Forced Expiratory Volume in 1 Second/Functional Vital Capacity Ratio (FEV1/FVC)(Change from baseline to 6 months post quit date)
  • Changes in Total Lung Capacity (TLC)(Change from baseline to 6 months post quit date)
  • Changes in Residual Volume to Total Lung Capacity (RV/TLC)(Change from baseline to 6 months post quit date)
  • Lung Clearance Index (LCI)(6 months post quit date)
  • Changes in Scond and Sacin(Change from baseline to 6 months post quit date)
  • Residual Volume (RV)(6 months post quit date)
  • Changes in Residual Volume (RV)(Change from baseline to 6 months post quit date)
  • Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)(6 months post quit date)
  • Changes in Forced Expiratory Volume in 1 Second (FEV1)(Change from baseline to 6 months post quit date)
  • Forced Expiratory Volume in 1 Second/Functional Vital Capacity Ratio (FEV1/FVC)(6 months post quit date)
  • Total Lung Capacity (TLC)(6 months post quit date)
  • Residual Volume to Total Lung Capacity (RV/TLC)(6 months post quit date)
  • Scond and Sacin(6 months post quit date)
  • Changes in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)(Change from baseline to 6 months post quit date)
  • Fraction of exhaled nitric oxide (FeNO)(6 months post quit date)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验